GR3021424T3 - Use of 3-guanidinopropionic acid in the manufacture of a medicament for the treatment and prevention of excess adiposity - Google Patents

Use of 3-guanidinopropionic acid in the manufacture of a medicament for the treatment and prevention of excess adiposity

Info

Publication number
GR3021424T3
GR3021424T3 GR960402796T GR960402796T GR3021424T3 GR 3021424 T3 GR3021424 T3 GR 3021424T3 GR 960402796 T GR960402796 T GR 960402796T GR 960402796 T GR960402796 T GR 960402796T GR 3021424 T3 GR3021424 T3 GR 3021424T3
Authority
GR
Greece
Prior art keywords
medicament
prevention
manufacture
treatment
guanidinopropionic acid
Prior art date
Application number
GR960402796T
Other languages
English (en)
Inventor
Martin Durham Meglasson
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of GR3021424T3 publication Critical patent/GR3021424T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Fodder In General (AREA)
GR960402796T 1990-02-28 1996-10-23 Use of 3-guanidinopropionic acid in the manufacture of a medicament for the treatment and prevention of excess adiposity GR3021424T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48661590A 1990-02-28 1990-02-28
PCT/US1991/000334 WO1991012799A1 (en) 1990-02-28 1991-01-22 Use of 3-guanidinopropionic acid in the treatment and prevention of metabolic disorders
PCT/US1991/001109 WO1991012800A1 (en) 1990-02-28 1991-02-27 Use of 3-guanidinopropionic acid in the treatment and prevention of metabolic disorders

Publications (1)

Publication Number Publication Date
GR3021424T3 true GR3021424T3 (en) 1997-01-31

Family

ID=26782896

Family Applications (1)

Application Number Title Priority Date Filing Date
GR960402796T GR3021424T3 (en) 1990-02-28 1996-10-23 Use of 3-guanidinopropionic acid in the manufacture of a medicament for the treatment and prevention of excess adiposity

Country Status (14)

Country Link
US (2) US5132324A (el)
EP (2) EP0517820B1 (el)
JP (2) JPH0825875B2 (el)
KR (1) KR100190257B1 (el)
AT (1) ATE141505T1 (el)
AU (2) AU7316591A (el)
CA (1) CA2073873C (el)
DE (1) DE69121561T2 (el)
DK (1) DK0517820T3 (el)
ES (1) ES2090317T3 (el)
GR (1) GR3021424T3 (el)
NZ (2) NZ237249A (el)
WO (2) WO1991012799A1 (el)
ZA (1) ZA911496B (el)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356913A (en) * 1990-02-09 1994-10-18 The Upjohn Company Use of insulin sensitizing agents to treat hypertension
US5900435A (en) * 1991-08-26 1999-05-04 Pharmacia & Upjohn Company Composition, food product and uses of 3-guanidinopropionic acid
US6008253A (en) * 1991-08-26 1999-12-28 The Upjohn Company Use of 3-guanidinopropionic acid to increase endurance, stamina and exercise capacity in a mammal
WO1993003714A2 (en) * 1991-08-27 1993-03-04 The Upjohn Company Method for treatment of metabolic disorders
AU6950294A (en) * 1993-05-14 1994-12-12 Amira, Inc. Treating body parts susceptible to ischemia using creatine analogs
US5808246A (en) * 1995-09-25 1998-09-15 Otis Elevator Company Triac drive for three-phase line-powered linear induction motor elevator door operator
EP0854712B1 (en) * 1995-10-11 2003-05-07 Avicena Group, Inc. Use of creatine analogues for the treatment of disorders of glucose metabolism
KR19990076594A (ko) * 1995-12-22 1999-10-15 피터 존 기딩스 Niddm 치료용 아미노구아니딘
DE19622222A1 (de) * 1996-06-03 1997-12-04 Hoechst Ag Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikament zur Normalisierung der Serumlipide
US20040122096A1 (en) * 1996-06-03 2004-06-24 Hoechst Aktiengesellschaft Use of inhibitors of the cellular Na+/H+ exchanger (NHE) for preparing a medicament for normalizing serum lipids
CA2280871A1 (en) * 1997-02-13 1998-08-20 Valerie Piercy Use of nitric oxide synthase inhibitors for the treatment of diabetes
US7910548B2 (en) * 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
WO2000010606A1 (fr) 1998-08-24 2000-03-02 Kurokawa, Kiyoshi Medicaments de sedation de l'agression du carbonyle et des dialysats peritoneaux
US7014307B2 (en) * 1998-11-09 2006-03-21 Silverbrook Research Pty Ltd Printing unit for an image recordal and generation apparatus
US20050027005A1 (en) * 2003-08-02 2005-02-03 Matthias Boldt Nutrient compositions and methods for sustenance and promotion of positive metabolic energy levels in a targeted manner
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
US7670849B2 (en) * 2005-04-29 2010-03-02 Henkin Robert I Method for diagnosing insulin resistance from nasal secretions
JP4777225B2 (ja) * 2006-12-04 2011-09-21 キヤノン株式会社 吐出用液体及び吐出方法
US8293489B2 (en) 2007-01-31 2012-10-23 Henkin Robert I Methods for detection of biological substances
US8580801B2 (en) * 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
WO2012138214A1 (en) * 2011-04-08 2012-10-11 Brewster Lizzy Maritza Beta-guanidinopropionic acid for the treatment of hypertension
US10598672B2 (en) 2014-02-18 2020-03-24 Cyrano Therapeutics, Inc. Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
CN105963250A (zh) * 2016-06-21 2016-09-28 俞力 一种口服葡萄糖溶液及其制备方法
KR102615692B1 (ko) 2021-10-13 2023-12-19 주식회사 휴엔켐 베타-구아니디노프로피온산을 포함하는 간섬유화 예방 또는 치료용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA891509A (en) * 1972-01-25 Beecham Group Limited Esters and amides of guanidine aliphatic acids
GB1153424A (en) * 1965-04-15 1969-05-29 Horlicks Ltd Pharmaceutical Compositions
GB1195199A (en) * 1966-11-25 1970-06-17 Horlicks Pharmaceuticals Ltd Improvements in Compositions comprising Insulin.
GB1195200A (en) * 1967-02-07 1970-06-17 Horlicks Pharmaceuticals Ltd Pharmaceutical Compositions.
US3843798A (en) * 1973-03-12 1974-10-22 Stanley Drug Products Inc Methods and compositions for inducing resistance to bacterial infections
GB1552179A (en) * 1976-11-02 1979-09-12 Beecham Group Ltd Pharmaceutical compositions for treating hyperglycaemia
US5900435A (en) * 1991-08-26 1999-05-04 Pharmacia & Upjohn Company Composition, food product and uses of 3-guanidinopropionic acid

Also Published As

Publication number Publication date
ZA911496B (en) 1991-12-24
JPH05505189A (ja) 1993-08-05
DE69121561D1 (de) 1996-09-26
ATE141505T1 (de) 1996-09-15
EP0713699A3 (el) 1996-07-10
CA2073873A1 (en) 1991-08-29
ES2090317T3 (es) 1996-10-16
AU645076B2 (en) 1994-01-06
US5134164A (en) 1992-07-28
DK0517820T3 (da) 1997-06-09
WO1991012800A1 (en) 1991-09-05
US5132324A (en) 1992-07-21
DE69121561T2 (de) 1997-01-30
WO1991012799A1 (en) 1991-09-05
AU7485091A (en) 1991-09-18
EP0713699A2 (en) 1996-05-29
JPH0820534A (ja) 1996-01-23
KR100190257B1 (ko) 1999-06-01
NZ237249A (en) 1994-09-27
EP0517820A1 (en) 1992-12-16
CA2073873C (en) 1996-10-29
EP0517820B1 (en) 1996-08-21
AU7316591A (en) 1991-09-18
JPH0825875B2 (ja) 1996-03-13
NZ245541A (en) 1997-05-26
JP2637712B2 (ja) 1997-08-06

Similar Documents

Publication Publication Date Title
GR3021424T3 (en) Use of 3-guanidinopropionic acid in the manufacture of a medicament for the treatment and prevention of excess adiposity
GR3032207T3 (en) 2-Bromomelatonin in the therapy of sleep disorders
IL125534A0 (en) A unit dose of budesonide and use thereof for nasal administration
GR3023874T3 (en) Igf-1 to improve the neural condition.
EP0494972A4 (en) Effervescent dosage form and method of administering same
IL112029A (en) Raloxifine and related compounds for use as medicaments for the treatment of disorders associated with an excess of tachykinin
DK0668763T3 (da) Anvendelse af phenserin til fremstillingen af lægemidler til behandlingen af kognitive sygdomme
IL98258A0 (en) Composition for treating impotence containing doxazosin,amlodipine,or u.k.52,046
DE68912195T2 (de) Verwendung von Pyrrolicloncarbonsäurealkylestern zur Herstellung eines Arzneimittels zur Behandlung von Ichtyosis.
GB8704190D0 (en) Therapeutic agent
GB9403855D0 (en) Fatty acid derivatives
ZA921292B (en) Treatment of lower urinary tract disorders.
EP0279887A3 (en) Carnitine directed pharmaceutical agents and their use for the manufacture of a medicament for the treatment of muscle disorder
GR3021813T3 (en) Method of treating alopecia
IE893611L (en) Liquid oral formulation
HU9402816D0 (en) Medicament for the treatment of airways inflammation and airways hyperresponsiveness
PL335802A1 (en) Method of treating vascular disorders
EP0458536A3 (en) Therapeutic agent for treatment and prevention of adult respiratory distress syndrome
MD1296G2 (ro) Metoda Nicolau de tratament al lichenului plan bucal
AU7907794A (en) Automated stop/start control in the administration of CPAP treatment
EG19885A (en) Medicament for the treatment of hyperlipidaemia and/or atherosolerosis
ZA879420B (en) 5-aryl-3h-1,2,4-triazol-3-ones and their use in the treatment of neurodegenerative disorders